Cargando…
Murine models of HRAS-mediated cutaneous skeletal hypophosphatemia syndrome suggest bone as the FGF23 excess source
Cutaneous skeletal hypophosphatemia syndrome (CSHS) is a mosaic RASopathy characterized by the association of dysplastic skeletal lesions, congenital skin nevi of epidermal and/or melanocytic origin, and FGF23-mediated hypophosphatemia. The primary physiological source of circulating FGF23 is bone c...
Autores principales: | Ovejero, Diana, Michel, Zachary, Cataisson, Christophe, Saikali, Amanda, Galisteo, Rebeca, Yuspa, Stuart H., Collins, Michael T., de Castro, Luis F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Clinical Investigation
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10145192/ https://www.ncbi.nlm.nih.gov/pubmed/36943390 http://dx.doi.org/10.1172/JCI159330 |
Ejemplares similares
-
SAT-LB085 First Report of Burosumab (Anti-FGF23 Monoclonal Antibody) for Rickets Complicating HRAS-Associated Cutaneous Skeletal Hypophosphatemia Syndrome
por: Smith, Pamela, et al.
Publicado: (2019) -
FGF23, Hypophosphatemia, and Emerging Treatments
por: Imel, Erik A, et al.
Publicado: (2019) -
A computationally identified compound antagonizes excess FGF-23 signaling in renal tubules and a mouse model of hypophosphatemia
por: Xiao, Zhousheng, et al.
Publicado: (2016) -
FGF23 and its role in X-linked hypophosphatemia-related morbidity
por: Beck-Nielsen, Signe Sparre, et al.
Publicado: (2019) -
Antibody-Mediated Activation of FGFR1 Induces FGF23 Production and Hypophosphatemia
por: Wu, Ai-Luen, et al.
Publicado: (2013)